Shots:
- Enhertu approval for previously treated adults with unresectable or metastatic HER2+ (IHC 3+) solid tumors & no satisfactory treatment option, was based on subgroup data from P-II trials, incl. DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02.
- In DESTINY-PanTumor02, Enhertu achieved a cORR of 52.3% & mDOR of 21.1mos. in previously treated HER2+ solid tumors (n=111), while DESTINY-Lung01 reported a cORR of 52.9% & mDOR of 6.9mos. in previously treated HER2+ NSCLC (n=17)
- In DESTINY-CRC02, Enhertu demonstrated a cORR of 46.9% & mDOR of 5.5mos. in previously treated HER2+ CRC pts (n=64). This approval triggers a milestone payment of $25M from AstraZeneca to Daiichi Sankyo
Ref: Businesswire | Image: Daiichi Sankyo & AstraZeneca | Press Release
Related News: Daiichi Sankyo and AstraZeneca Report the CHMP Positive Opinion for Datroway to Treat Metastatic Triple Negative Breast Cancer
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
